A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

NCT06780137 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

262

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

BIOLOGICAL: Gocatamig
BIOLOGICAL: Ifinatamab Deruxtecan (I-DXd)
BIOLOGICAL: Durvalumab

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]